In one study, LINC00152 was found to promote tumor growth through an EGFR-mediated PI3/AKT pathway in gastric cancer cell lines, MGC803 and HGC-2715, whereas in another study with gastric cell lines BGC-823 and SGC-7901 cells, LINC00152 promoted GC tumor cell cycle progression by binding to enhancer of zeste homolog 2 (EZH2), thus silencing the expression of p15 and p2131. Here, EZH2 is linked to gastric cancer.